{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:21:14Z","timestamp":1780370474246,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00393-017-0329-x","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:44:01Z","timestamp":1496738641000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Wirksamkeits- und Sicherheitsanalyse von Off-label-Biologikatherapien bei Patienten mit autoinflammatorischen Erkrankungen","Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases"],"prefix":"10.1007","volume":"77","author":[{"given":"F.","family":"Proft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"issue":"4","key":"329_CR1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0092-8674(00)80539-5","volume":"90","author":"The International FMF Consortium","year":"1997","unstructured":"The International FMF Consortium (1997) Ancient missense mutations in a\u00a0new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797\u2013807","journal-title":"Cell"},{"issue":"1","key":"329_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"French FMFC","year":"1997","unstructured":"French FMFC (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25\u201331","journal-title":"Nat Genet"},{"issue":"3","key":"329_CR3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archderm.144.3.392","volume":"144","author":"S Farasat","year":"2008","unstructured":"Farasat S, Aksentijevich I, Toro JR (2008) Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 144(3):392\u2013402","journal-title":"Arch Dermatol"},{"issue":"4","key":"329_CR4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.37827","volume":"65","author":"T Lane","year":"2013","unstructured":"Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL et\u00a0al (2013) AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65(4):1116\u20131121","journal-title":"Arthritis Rheum"},{"issue":"23","key":"329_CR5","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et\u00a0al (2007) Natural history and outcome in systemic AA amyloidosis. N\u00a0Engl J Med 356(23):2361\u20132371","journal-title":"N Engl J Med"},{"issue":"1","key":"329_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.autrev.2012.07.016","volume":"12","author":"L Obici","year":"2012","unstructured":"Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12(1):14\u201317","journal-title":"Autoimmun Rev"},{"issue":"5","key":"329_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12(5):259\u2013268","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"329_CR8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10067-015-2923-0","volume":"34","author":"D Rigante","year":"2015","unstructured":"Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L (2015) Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 34(8):1333\u20131339","journal-title":"Clin Rheumatol"},{"issue":"5","key":"329_CR9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2005.042143","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still\u2019s disease. Ann Rheum Dis 65(5):564\u2013572","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"329_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0049-0172(87)90015-1","volume":"17","author":"AJ Reginato","year":"1987","unstructured":"Reginato AJ, Schumacher HR Jr., Baker DG, O\u2019Connor CR, Ferreiros J (1987) Adult onset Still\u2019s disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 17(1):39\u201357","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"329_CR11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM Haar ter","year":"2015","unstructured":"ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA et\u00a0al (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636\u20131644","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"329_CR12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644\u2013651","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"329_CR13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302\u2013308","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"329_CR14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","volume":"69","author":"L Naumann","year":"2010","unstructured":"Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F et al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease. Ann Rheum Dis 69(2):466\u2013467","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"329_CR15","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"PN Hawkins","year":"2003","unstructured":"Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N\u00a0Engl J Med 348(25):2583\u20132584","journal-title":"N Engl J Med"},{"issue":"23","key":"329_CR16","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N\u00a0Engl J Med 360(23):2416\u20132425","journal-title":"N Engl J Med"},{"issue":"12","key":"329_CR17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B et al (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095\u20132102","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"329_CR18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V et al (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62(1):258\u2013267","journal-title":"Arthritis Rheum"},{"issue":"39","key":"329_CR19","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanjuan","year":"2015","unstructured":"Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, Castaneda S, Olive A, Riveros A et al (2015) Efficacy of Anakinra in refractory adult-onset still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"329_CR20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et\u00a0al (2005) Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis 64(2):262\u2013266","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"329_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Puechal","year":"2011","unstructured":"Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O et\u00a0al (2011) Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res (Hoboken) 63(1):155\u2013159","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"329_CR22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11882-008-0047-1","volume":"8","author":"RL Glaser","year":"2008","unstructured":"Glaser RL, Goldbach-Mansky R (2008) The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 8(4):288\u2013298","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"329_CR23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3899\/jrheum.091046","volume":"37","author":"M Durand","year":"2010","unstructured":"Durand M, Troyanov Y, Laflamme P, Gregoire G (2010) Macrophage activation syndrome treated with anakinra. J\u00a0Rheumatol 37(4):879\u2013880","journal-title":"J Rheumatol"},{"issue":"11","key":"329_CR24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4(11):615\u2013620","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"329_CR25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A (2011) Benefit and a\u00a0possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21(1):92\u201396","journal-title":"Mod Rheumatol"},{"issue":"1","key":"329_CR26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/s10165-011-0477-9","volume":"22","author":"K Maeshima","year":"2012","unstructured":"Maeshima K, Ishii K, Iwakura M, Akamine M, Hamasaki H, Abe I et al (2012) Adult-onset Still\u2019s disease with macrophage activation syndrome successfully treated with a\u00a0combination of methotrexate and etanercept. Mod Rheumatol 22(1):137\u2013141","journal-title":"Mod Rheumatol"},{"issue":"16","key":"329_CR27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2169\/internalmedicine.50.4771","volume":"50","author":"Y Yoshida","year":"2011","unstructured":"Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T (2011) Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a\u00a0case of multiple drug-resistant adult-onset Still\u2019s disease. Intern Med 50(16):1757\u20131760","journal-title":"Intern Med"},{"key":"329_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.006","author":"S Ozen","year":"2017","unstructured":"Ozen S, Kone-Paut I, Gul A (2017) Colchicine resistance and intolerance in familial Mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. doi:\n                        10.1016\/j.semarthrit.2017.03.006","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"329_CR29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-017-0609-1","volume":"12","author":"A Corsia","year":"2017","unstructured":"Corsia A, Georgin-Lavialle S, Hentgen V, Hachulla E, Grateau G, Faye A et al (2017) A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis 12(1):54","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 4","key":"329_CR30","first-page":"615","volume":"69","author":"FAJ Benedetti De","year":"2016","unstructured":"De Benedetti FAJ, Ben-Chetrit E, Calvo I, Frenkel J, Gattorno M, Hoffman HM, Kasapcopur O, Kon\u00e9-Paut I, Lachmann H, Moutschen M, Ozen S, Quartier P, Simon A, Zeft A, Lheritier K, Speziale A, Junge G (2016) A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS\/MKD and TRAPS). Annals of the Rheumatic Diseases 2016;75:615\u2013616.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"329_CR31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","volume":"55","author":"T Kullenberg","year":"2016","unstructured":"Kullenberg T, Lofqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H (2016) Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford) 55(8):1499\u20131506","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"329_CR32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J et al (2013) Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 65(5):822\u2013826","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0329-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T08:21:36Z","timestamp":1517818896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0329-x"}},"subtitle":["Erfahrungen aus einem Deutschen Register (GRAID2)","Experiences from a\u00a0German registry\u00a0(GRAID2)"],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0329-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}